PTGX - Company ID 0001377121
The table below shows Protagonist Therapeutics, Inc's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $46.02M | $434.43M | $60.00M | $26.58M | $27.36M | $28.63M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $159.29M | $138.13M | $120.16M | $126.22M | $126.01M | $74.51M |
| SG&A |
Protagonist Therapeutics, Inc reported annual revenue of $46.02M for fiscal year 2025. That is down 89.4% from $434.43M in fiscal 2024. Over the 9 fiscal years shown, annual revenue grew from $20.06M (FY 2017) to $46.02M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $44.85M |
| $43.46M |
| $33.49M |
| $31.74M |
| $27.20M |
| $18.64M |
| Operating income | -$158.13M | $252.84M | -$93.65M | -$131.37M | -$125.84M | -$64.52M |
| Income tax | $838.00K | $4.22M | $0.00 | $0.00 | $0.00 | $1.30M |
| Net income | -$130.15M | $275.19M | -$78.96M | -$127.39M | -$125.55M | -$66.15M |
| EPS (diluted) | -$2.05 | $4.23 | -$1.39 | -$2.60 | -$2.71 | -$1.92 |